KR101616022B1 - 류마티스 관절염 또는 급성 골수성 백혈병을 치료하기 위한 시클로펜타〔ｇ〕퀴나졸린 유도체 - Google Patents

류마티스 관절염 또는 급성 골수성 백혈병을 치료하기 위한 시클로펜타〔ｇ〕퀴나졸린 유도체 Download PDF

Info

Publication number
KR101616022B1
KR101616022B1 KR1020107023279A KR20107023279A KR101616022B1 KR 101616022 B1 KR101616022 B1 KR 101616022B1 KR 1020107023279 A KR1020107023279 A KR 1020107023279A KR 20107023279 A KR20107023279 A KR 20107023279A KR 101616022 B1 KR101616022 B1 KR 101616022B1
Authority
KR
South Korea
Prior art keywords
cyclopenta
cells
folate
pharmaceutical composition
phenylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020107023279A
Other languages
English (en)
Korean (ko)
Other versions
KR20110002848A (ko
Inventor
그리트 얀센
앤 잭맨
Original Assignee
비티지 인터내셔널 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0805035A external-priority patent/GB0805035D0/en
Priority claimed from GB0805036A external-priority patent/GB0805036D0/en
Application filed by 비티지 인터내셔널 리미티드 filed Critical 비티지 인터내셔널 리미티드
Publication of KR20110002848A publication Critical patent/KR20110002848A/ko
Application granted granted Critical
Publication of KR101616022B1 publication Critical patent/KR101616022B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020107023279A 2008-03-18 2009-03-13 류마티스 관절염 또는 급성 골수성 백혈병을 치료하기 위한 시클로펜타〔ｇ〕퀴나졸린 유도체 Active KR101616022B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0805035A GB0805035D0 (en) 2008-03-18 2008-03-18 Us eof cyclopenta[G]quinazoline derivatives
GB0805036.1 2008-03-18
GB0805035.3 2008-03-18
GB0805036A GB0805036D0 (en) 2008-03-18 2008-03-18 New use of cyclopenta[g]quinazoline derivatives

Publications (2)

Publication Number Publication Date
KR20110002848A KR20110002848A (ko) 2011-01-10
KR101616022B1 true KR101616022B1 (ko) 2016-04-28

Family

ID=40599662

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107023279A Active KR101616022B1 (ko) 2008-03-18 2009-03-13 류마티스 관절염 또는 급성 골수성 백혈병을 치료하기 위한 시클로펜타〔ｇ〕퀴나졸린 유도체

Country Status (10)

Country Link
US (1) US8466111B2 (OSRAM)
EP (1) EP2293807B1 (OSRAM)
JP (1) JP5599773B2 (OSRAM)
KR (1) KR101616022B1 (OSRAM)
CN (1) CN101977620B (OSRAM)
AT (1) ATE556715T1 (OSRAM)
CA (1) CA2717954C (OSRAM)
DK (1) DK2293807T3 (OSRAM)
ES (1) ES2387334T3 (OSRAM)
WO (1) WO2009115776A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028918T2 (en) * 2010-12-22 2017-01-30 Btg Int Ltd Effective peptide couplings and their use in the synthesis and isolation of cyclopenta (G) quinazoline trinodium salt
EA201990473A1 (ru) 2016-08-12 2019-07-31 Эл.И.Эй.Эф. ХОЛДИНГС ГРУП ЭлЭлСи Полиглутамированные антифолаты и их применение
WO2018031967A1 (en) 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Polyglutamated antifolates and uses thereof
GB201707864D0 (en) 2017-05-16 2017-06-28 Inst Of Cancer Research: Royal Cancer Hospital Platinum-reistant cancer treatment
EP3749311A4 (en) 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC PEMETREXED POLYGLUTAMATE GAMMA COMPOSITIONS AND THEIR USES
CA3090506A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated tetrahydrofolates and uses thereof
US12076402B2 (en) 2018-02-07 2024-09-03 L.E.A.F. Holdings Group Llc Alpha polyglutamated antifolates and uses thereof
EP3749316A4 (en) 2018-02-07 2021-10-27 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATED PRALATREXATE AND USES THEREOF
CA3090389A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
US11779584B2 (en) 2018-02-07 2023-10-10 L.E.A.F. Holdings Group Llc Alpha polyglutamated pemetrexed and uses thereof
EP3749312A4 (en) 2018-02-07 2022-02-23 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATED LOMETREXOLE AND USES THEREOF
CN111954529A (zh) 2018-02-07 2020-11-17 L.E.A.F.控股集团公司 α聚谷氨酸化氨甲蝶呤及其用途
WO2019157123A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
EP3749318A4 (en) 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES
CA3090943A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
US11771700B2 (en) 2018-02-14 2023-10-03 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
EP3752156A4 (en) * 2018-02-14 2021-10-27 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMIZED PRALATREXATE AND USES THEREOF
CN111936145A (zh) 2018-02-14 2020-11-13 L.E.A.F.控股集团公司 γ聚谷氨酸化氨甲蝶呤及其用途
US12048766B2 (en) 2018-02-14 2024-07-30 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
WO2019169029A1 (en) * 2018-02-28 2019-09-06 Bioxiness Pharmaceuticals, Inc. Target specific chemotherapeutic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223352D0 (en) 1992-11-06 1992-12-23 Ici Plc Tricyclic compounds
GB9408936D0 (en) * 1994-05-05 1994-06-22 Cancer Res Inst Anti-cancer compounds
US7297701B2 (en) * 2001-08-31 2007-11-20 Btg International Limited Anti-cancer cyclopenta [G]quinazoline compounds
WO2003020300A1 (en) * 2001-08-31 2003-03-13 Btg International Limited Use of cyclopenta[g]quinazoline derivatives for treating cancer
CA2503094A1 (en) * 2002-02-27 2003-09-04 The Ohio State University Research Foundation Therapeutic methods for acute myeloid leukemia

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Advanced Drug Delivery Reviews. Vol.56(8), pp.1111-1125
Bioorganic & Medicinal Chemistry. Vol.14(14), pp.5020-5042 (2006)*
Cancer Research. Vol.63(13), pp.3612-3618
Cancer Research. Vol.65(24), pp.11721-11728

Also Published As

Publication number Publication date
US8466111B2 (en) 2013-06-18
HK1154786A1 (en) 2012-05-04
CA2717954A1 (en) 2009-09-24
CA2717954C (en) 2019-06-04
EP2293807B1 (en) 2012-05-09
DK2293807T3 (da) 2012-07-23
KR20110002848A (ko) 2011-01-10
ATE556715T1 (de) 2012-05-15
JP5599773B2 (ja) 2014-10-01
JP2011515384A (ja) 2011-05-19
CN101977620B (zh) 2014-05-07
WO2009115776A1 (en) 2009-09-24
US20110190211A1 (en) 2011-08-04
ES2387334T3 (es) 2012-09-20
EP2293807A1 (en) 2011-03-16
CN101977620A (zh) 2011-02-16

Similar Documents

Publication Publication Date Title
JP5599773B2 (ja) リウマチ様関節炎又は急性骨髄性白血病の治療のためのシクロペンタ［ｇ］キナゾリン誘導体
Van Der Heijden et al. Folate receptor β as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients
JP6712427B2 (ja) 移植片対宿主病を処置し予防する方法
TWI831740B (zh) 用於car t細胞療法之組合物及方法
JP2026048860A (ja) 抗体－薬物コンジュゲートとａｔｒ阻害剤との組み合わせ
EP3903828A1 (en) Combination of antibody-drug conjugate and kinase inhibitor
CA2994544C (en) Compositions and methods for treating cancers associated with etbr activation
JP2020105181A (ja) 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法
CA3218253A1 (en) Dosing regimens of peptide conjugates of topoisomerase i inhibitors
WO2014018862A1 (en) Pharmaceutical compositions comprising a heat shock protein inhibitor and a|purine de novo synthesis inhibitor for treating rheumatoid arthritis or cancer
TW201900176A (zh) 鉑類耐藥性癌症治療
US8940701B2 (en) Compounds for, and methods of, treating cancer and inhibiting invasion and metastases
PL235635B1 (pl) Pochodna kwasu 7-aminocefalosporanowego-cefazolina oraz zawierający ją preparat farmaceutyczny do zastosowania w leczeniu i zapobieganiu chorób, u podłoża których leży nadmierna produkcja interleukiny 15 oraz interleukiny 2
HK1154786B (en) Cyclopenta[g]quinazoline derivatives for the treatment of rheumatoid arthritis or acute myeloid leukaemia
CN101267837B (zh) 用于治疗系统性肥大细胞增生症的组合物
WO2025214358A1 (zh) 用于治疗胰腺癌的药物及其用途
EA049478B1 (ru) Комбинация конъюгата антитела и лекарственного средства и ингибитора atr
WO2023086821A1 (en) Targeted therapy of pyrrolo[2,3-d]pyrimidine antifolates in a syngeneic mouse model of high grade serous ovarian cancer
HK40031991B (zh) 治疗和预防移植物抗宿主病的方法
HK40031991A (en) Methods of treating and preventing graft versus host disease
HK40054690A (en) Combination of antibody-drug conjugate and kinase inhibitor
Laan Sensitivity to methotrexate and novel antifolates in human squamous carcinoma cell lines of the head and neck
EA052071B1 (ru) Двойные ингибиторы путей tim-3 и pd-1

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 11